Patritumab Deruxtecan (HER3-DXd) in EGFR-Mutated Non-Small-Cell Lung Cancer

Dr. Yu and Dr. Patel provide an overview of current standards and recent advances in the treatment landscape for EGFR-mutated NSCLC, emphasizing the critical role of comprehensive genomic profiling in guiding optimal therapy selection and sequencing.

Expert medical oncologists examine remaining unmet needs in managing EGFR-positive lung cancer, including overcoming resistance to initial EGFR-directed therapy. The panel discusses ongoing trials targeting these needs.

Dr. Patel and Dr. Yu review the rationale for targeting HER3 as a novel approach to address acquired resistance in EGFR-mutant NSCLC.

The expert panel analyze results from the HERTHENA-Lung01 trial, discuss efficacy outcomes with patritumab deruxtecan in pretreated EGFR-mutant metastatic NSCLC.

Helena A. Yu, MD, and Sandip P. Patel, MD, reviewed the use of patritumab deruxtecan, which was assessed in the phase 2 HERTHENA-Lung01 trial.

Dr. Yu and Dr. Patel examine the safety profile of patritumab deruxtecan, including adverse event monitoring and management approaches to optimize patient outcomes.

The panel discusses how HER3-directed therapy with patritumab deruxtecan may fit into the evolving treatment paradigm for EGFR-positive lung cancer as more data emerges.